3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?

45
13
Favorite

3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?

Motley Fool2021-04-15

These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（13）

rocat
·2021-04-15
Bleed
Reply
2
Report
Fold Replies
- Qaal:
  Test comment 2
  2021-04-16
  Reply
  Report
- Qaal:
  Test comment
  2021-04-16
  Reply
  Report
- Qaal:
  Waterfall
  2021-04-16
  Reply
  Report
kolusoe69
·2021-04-15
Nice
Reply
5
Report
Fold Replies
- PKK:
  Naise
  2021-04-15
  Reply
  Report
weiliat
·2021-04-15
Bngo just anther joke
Reply
Like
Report
FlyMeToMoon
·2021-04-15
Who is vested in any of these three? I’m in cannabis. Please like and comment. Thanks!
Reply
1
Report
Chachacha
·2021-04-15
Bngo!
Reply
Like
Report
labbygabby
·2021-04-15
Like and comment
Reply
3
Report
Fold Replies
- Ahpo:
  huat~
  2021-04-15
  Reply
  Report
OJC
·2021-04-15
Huat arh
Reply
2
Report
Fold Replies
- OJC:
  ??
  2021-04-15
  Reply
  Report
njkk
·2021-04-15
Pls like and comment :)
Reply
3
Report
Fold Replies
- KKSV:
  ???
  2021-04-15
  Reply
  Report
MARCC
·2021-04-15
Like here and comment!
Reply
3
Report
Fold Replies
- Cucumbers:
  Sounds risky to get now
  2021-04-15
  Reply
  Report
Bin8
·2021-04-15
no, don't think will buy them.
Reply
1
Report
Fold Replies
- Bin8:
  don't think so.
  2021-04-18
  Reply
  Report
- Bin8:
  testing
  2021-04-16
  Reply
  Report
Jekanath
·2021-04-15
Yes!
Reply
Like
Report
JORDBULL
·2021-04-15
Hmm
Reply
1
Report
Jay028
·2021-04-15
Like pls :)
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2127001675?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-15 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2127001675","market":"us","top_or_hot":-1,"title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","media":"Motley Fool","content":"<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","article_id":"2127001675","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","pubTimestamp":1618483800,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics","OCGN":"Ocugen","APHA":"Aphria Inc."},"translate_title":"32021年翻了一倍多的罗宾汉股票：他们现在买进了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APHA":0.9,"BNGO":0.9,"OCGN":0.9},"content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":347592334,"gmtCreate":1618500022328,"gmtModify":1704711915390,"author":{"id":"3576405243338366","authorId":"3576405243338366","name":"rocat","avatar":"https://static.tigerbbs.com/e537c7a4cf09b6014ec1c1754eac4da9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576405243338366","authorIdStr":"3576405243338366"},"htmlText":"Bleed","listText":"Bleed","text":"Bleed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/347592334","repostId":2127001675,"repostType":2,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4051397,"gmtCreate":1618558466453,"gmtModify":1680784311456,"authorId":3577432645863048,"author":{"id":3577432645863048,"idStr":"3577432645863048","authorId":3577432645863048,"name":"Qaal","avatar":"https://static.tigerbbs.com/0ebae6fa58e32daca8a545858cb2b589","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347592334,"type":1,"supId":0,"prevId":0,"content":"Test comment <u>2</u>","text":"Test comment <u>2</u>","html":"Test comment <u>2</u>"},{"id":4051395,"gmtCreate":1618558448931,"gmtModify":1680784310204,"authorId":3577432645863048,"author":{"id":3577432645863048,"idStr":"3577432645863048","authorId":3577432645863048,"name":"Qaal","avatar":"https://static.tigerbbs.com/0ebae6fa58e32daca8a545858cb2b589","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347592334,"type":1,"supId":0,"prevId":0,"content":"Test <u>comment</u>","text":"Test <u>comment</u>","html":"Test <u>comment</u>"},{"id":4046514,"gmtCreate":1618515889545,"gmtModify":1680784226599,"authorId":3577432645863048,"author":{"id":3577432645863048,"idStr":"3577432645863048","authorId":3577432645863048,"name":"Qaal","avatar":"https://static.tigerbbs.com/0ebae6fa58e32daca8a545858cb2b589","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347592334,"type":1,"supId":0,"prevId":0,"content":"Waterfall","text":"Waterfall","html":"Waterfall"}],"langContent":"EN"},{"id":347874332,"gmtCreate":1618490146126,"gmtModify":1704711614256,"author":{"id":"3574239659963867","authorId":"3574239659963867","name":"kolusoe69","avatar":"https://static.tigerbbs.com/0b993172cb0fc67ef903f8a6103d9517","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574239659963867","authorIdStr":"3574239659963867"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/347874332","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4045019,"gmtCreate":1618497703173,"gmtModify":1680784206170,"authorId":3569284910665387,"author":{"id":3569284910665387,"idStr":"3569284910665387","authorId":3569284910665387,"name":"PKK","avatar":"https://static.tigerbbs.com/41f14a1f96fe8ea10f7149244bb4a97a","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347874332,"type":1,"supId":0,"prevId":0,"content":"Naise","text":"Naise","html":"Naise"}],"langContent":"EN"},{"id":347871381,"gmtCreate":1618489676543,"gmtModify":1704711608101,"author":{"id":"3576119800068743","authorId":"3576119800068743","name":"weiliat","avatar":"https://static.tigerbbs.com/1ac8cb0d9a81d56d9e0f2ee477362395","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":1,"crmLevelSwitch":0,"idStr":"3576119800068743","authorIdStr":"3576119800068743"},"htmlText":"Bngo just anther joke","listText":"Bngo just anther joke","text":"Bngo just anther joke","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347871381","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347851195,"gmtCreate":1618487914017,"gmtModify":1704711578758,"author":{"id":"3575520487539106","authorId":"3575520487539106","name":"FlyMeToMoon","avatar":"https://static.tigerbbs.com/413aa048c40df6d6701a19b17e1a3c47","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575520487539106","authorIdStr":"3575520487539106"},"htmlText":"Who is vested in any of these three? I’m in&nbsp;cannabis.&nbsp;Please like and comment. Thanks!&nbsp;","listText":"Who is vested in any of these three? I’m in&nbsp;cannabis.&nbsp;Please like and comment. Thanks!&nbsp;","text":"Who is vested in any of these three? I’m in cannabis. Please like and comment. Thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347851195","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347821448,"gmtCreate":1618486749284,"gmtModify":1704711565515,"author":{"id":"3561441128648127","authorId":"3561441128648127","name":"Chachacha","avatar":"https://static.tigerbbs.com/6d6b731ce73eb4a18c3505cf98c74a66","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3561441128648127","authorIdStr":"3561441128648127"},"htmlText":"Bngo!","listText":"Bngo!","text":"Bngo!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347821448","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347821684,"gmtCreate":1618486705048,"gmtModify":1704711565021,"author":{"id":"3570622042872208","authorId":"3570622042872208","name":"labbygabby","avatar":"https://static.tigerbbs.com/fa797ffcaf2dfcc6d6c6457f3cd25536","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570622042872208","authorIdStr":"3570622042872208"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/347821684","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4043393,"gmtCreate":1618486790714,"gmtModify":1680784182935,"authorId":3577678632737367,"author":{"id":3577678632737367,"idStr":"3577678632737367","authorId":3577678632737367,"name":"Ahpo","avatar":"https://static.tigerbbs.com/f8518a7ad2456fedc5094daf9dbd2f57","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.66%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347821684,"type":1,"supId":0,"prevId":0,"content":"huat~","text":"huat~","html":"huat~"}],"langContent":"EN"},{"id":347867208,"gmtCreate":1618486281304,"gmtModify":1704711560400,"author":{"id":"3558657051587432","authorId":"3558657051587432","name":"OJC","avatar":"https://static.tigerbbs.com/12cbec786aa0456d41fb74009ec04a37","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":7,"crmLevelSwitch":0,"idStr":"3558657051587432","authorIdStr":"3558657051587432"},"htmlText":"Huat arh","listText":"Huat arh","text":"Huat arh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/347867208","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4043343,"gmtCreate":1618486376324,"gmtModify":1680784179182,"authorId":3558657051587432,"author":{"id":3558657051587432,"idStr":"3558657051587432","authorId":3558657051587432,"name":"OJC","avatar":"https://static.tigerbbs.com/12cbec786aa0456d41fb74009ec04a37","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.16","exceedPercentage":"93.25%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347867208,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"},{"id":347868185,"gmtCreate":1618485652747,"gmtModify":1704711552814,"author":{"id":"3575950181915531","authorId":"3575950181915531","name":"njkk","avatar":"https://static.tigerbbs.com/6382201e8e84ccd3f8e89b9a28e74607","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575950181915531","authorIdStr":"3575950181915531"},"htmlText":"Pls like and comment :)","listText":"Pls like and comment :)","text":"Pls like and comment :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/347868185","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4043440,"gmtCreate":1618487220828,"gmtModify":1680784181406,"authorId":3577785816786397,"author":{"id":3577785816786397,"idStr":"3577785816786397","authorId":3577785816786397,"name":"KKSV","avatar":"https://static.tigerbbs.com/af79ae4e2c2eee7b0446d54673c5439e","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347868185,"type":1,"supId":0,"prevId":0,"content":"???","text":"???","html":"???"}],"langContent":"EN"},{"id":347860874,"gmtCreate":1618485219398,"gmtModify":1704711547553,"author":{"id":"3558340642160988","authorId":"3558340642160988","name":"MARCC","avatar":"https://community-static.tradeup.com/news/5d2032c0e6cc39e667e6c80eaaedc251","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3558340642160988","authorIdStr":"3558340642160988"},"htmlText":"Like here and comment!","listText":"Like here and comment!","text":"Like here and comment!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/347860874","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4043229,"gmtCreate":1618485299603,"gmtModify":1680784181200,"authorId":3576794201858255,"author":{"id":3576794201858255,"idStr":"3576794201858255","authorId":3576794201858255,"name":"Cucumbers","avatar":"https://static.tigerbbs.com/e738e1e68e462d14f96cf6ac301fbd37","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.16","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347860874,"type":1,"supId":0,"prevId":0,"content":"Sounds risky to get now ","text":"Sounds risky to get now ","html":"Sounds risky to get now "}],"langContent":"EN"},{"id":347884418,"gmtCreate":1618485055734,"gmtModify":1704711545024,"author":{"id":"3581566554984741","authorId":"3581566554984741","name":"Bin8","avatar":"https://static.tigerbbs.com/d4547f1e0822b414bcadb0942d311dbc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3581566554984741","authorIdStr":"3581566554984741"},"htmlText":"no, don't think will buy them.","listText":"no, don't think will buy them.","text":"no, don't think will buy them.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/347884418","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4062040,"gmtCreate":1618699643788,"gmtModify":1680784478735,"authorId":3581566554984741,"author":{"id":3581566554984741,"idStr":"3581566554984741","authorId":3581566554984741,"name":"Bin8","avatar":"https://static.tigerbbs.com/d4547f1e0822b414bcadb0942d311dbc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347884418,"type":1,"supId":0,"prevId":0,"content":"don't think so.","text":"don't think so.","html":"don't think so."},{"id":4048836,"gmtCreate":1618535772598,"gmtModify":1680784270686,"authorId":3581566554984741,"author":{"id":3581566554984741,"idStr":"3581566554984741","authorId":3581566554984741,"name":"Bin8","avatar":"https://static.tigerbbs.com/d4547f1e0822b414bcadb0942d311dbc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347884418,"type":1,"supId":0,"prevId":0,"content":"<u>testing</u>","text":"<u>testing</u>","html":"<u>testing</u>"}],"langContent":"EN"},{"id":347884501,"gmtCreate":1618485044003,"gmtModify":1704711545356,"author":{"id":"3573831225735802","authorId":"3573831225735802","name":"Jekanath","avatar":"https://static.tigerbbs.com/4a9b5ab382ec4c5241c28565fb086c28","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3573831225735802","authorIdStr":"3573831225735802"},"htmlText":"Yes!","listText":"Yes!","text":"Yes!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347884501","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347885685,"gmtCreate":1618484853147,"gmtModify":1704711543224,"author":{"id":"3567123115497130","authorId":"3567123115497130","name":"JORDBULL","avatar":"https://static.tigerbbs.com/4b95853b965a467335a4ba3aa97aa3df","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3567123115497130","authorIdStr":"3567123115497130"},"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347885685","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347886750,"gmtCreate":1618484697070,"gmtModify":1704711540955,"author":{"id":"3577322478204325","authorId":"3577322478204325","name":"Jay028","avatar":"https://static.tigerbbs.com/d27c6a8e1b7314d605ab1d70bce83d34","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3577322478204325","authorIdStr":"3577322478204325"},"htmlText":"Like pls :)&nbsp;","listText":"Like pls :)&nbsp;","text":"Like pls :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347886750","repostId":2127001675,"repostType":4,"repost":{"id":"2127001675","kind":"highlight","pubTimestamp":1618483800,"share":"https://ttm.financial/m/news/2127001675?lang=&edition=fundamental","pubTime":"2021-04-15 18:50","market":"us","language":"en","title":"3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001675","media":"Motley Fool","summary":"These stocks are red-hot so far this year. But could they cool off in the coming months?","content":"<blockquote><b>These stocks are red-hot so far this year. But could they cool off in the coming months?</b></blockquote><p>Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.</p><p>You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.</p><p><img src=\"https://static.tigerbbs.com/d8fcf5763d8ca2f10309e3f278c4e0b7\" tg-width=\"700\" tg-height=\"473\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h3>Aphria</h3><p><b>Aphria</b> (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind only<b>Sundial Growers</b>. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.</p><p>The biggest factor driving investors' interest in Aphria is the company's plans to merge with<b>Tilray</b> (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.</p><p>Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto its<b>Nasdaq</b>&nbsp;listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.</p><h3><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></h3><p>There's a genomics revolution underway right now. Surprisingly, though, only <a href=\"https://laohu8.com/S/AONE\">one</a> pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger is<b>Bionano Genomics</b> (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.</p><p>Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.</p><p>Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.</p><h3>Ocugen</h3><p><b>Ocugen</b> (NASDAQ:OCGN) stands out as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.</p><p>Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.</p><p>Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.</p><p><b>Are they buys now?</b></p><p>There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.</p><p>For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.</p><p>Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.</p><p>What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.</p><p>Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 18:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics","APHA":"Aphria Inc.","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/04/15/3-robinhood-stocks-that-have-more-than-doubled-in/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001675","content_text":"These stocks are red-hot so far this year. But could they cool off in the coming months?Winning goes hand-in-hand with popularity. It's true in sports. And it's true in investing.You probably won't be surprised, therefore, that many of the most popular stocks on the Robinhood trading platform have delivered impressive gains over the last few months. That doesn't necessarily mean that their sizzling momentum will continue, though. Here are three Robinhood stocks that have more than doubled so far in 2021 -- and a look at whether they're still good picks to buy now.Image source: Getty Images.AphriaAphria (NASDAQ:APHA) ranks as the second-highest marijuana stock in the top 100 most widely held stocks for Robinhood investors. It trails behind onlySundial Growers. But while Sundial's huge gains have dwindled enough to put the stock up by \"only\" 90% or so in 2021, Aphria's shares have soared 106% year to date.The biggest factor driving investors' interest in Aphria is the company's plans to merge withTilray (NASDAQ:TLRY). This deal will make the combined entity, which will assume the Tilray name, the largest cannabis company in the world.Another key reason for Aphria's ascent, though, is the increased probability that major cannabis reform will be enacted in the U.S. Aphria can't jump into the U.S. cannabis market and hold onto itsNasdaq listing as long as marijuana remains illegal at the federal level. However, the prospects of marijuana decriminalization could set the stage for Aphria and other Canadian cannabis producers to expand into the lucrative U.S. market.Bionano GenomicsThere's a genomics revolution underway right now. Surprisingly, though, only one pure-play genomics stock is in the top 100 most popular list on Robinhood. That lone ranger isBionano Genomics (NASDAQ:BNGO). The stock has been a major winner so far this year, with Bionano's shares vaulting 108% higher.Bionano had generated even bigger gains earlier in 2021. By mid-February, the stock had more than quintupled year to date. However, a shift away from high-flying growth stocks caused Bionano's share price to tumble over the last couple of months.Many investors remain enthusiastic about the company's prospects. Bionano beat analysts' Q4 revenue expectations. It expects to soon win accreditation in select European markets for Saphyr-based laboratory-developed tests for acute lymphocytic leukemia (ALL) and facioscapulohumeral muscular dystrophy (FSHD). The genomics testing company also thinks that it will have 150 Saphyr gene-sequencing systems installed by the end of this year, which would represent a 50% increase year over year.OcugenOcugen (NASDAQ:OCGN) stands out as one of the biggest winners among the top 100 Robinhood stocks. Shares of the biotech have skyrocketed 277% year to date. At one point this year, Ocugen was up more than 750%.Until late 2020, Ocugen's primary focus was its gene therapy candidates targeting eye disease. However, in late December the company announced a partnership with Bharat Biotech to co-develop COVID-19 vaccine Covaxin for the U.S. market.Covaxin has already won authorization in India. Bharat reported results from a late-stage study conducted in the country that demonstrated an 81% efficacy rate. Ocugen stands to receive 45% of any profits if the vaccine is authorized or approved for sale in the U.S. The company is working with U.S. regulatory authorities to develop a path for Emergency Use Authorization (EUA) for Covaxin.Are they buys now?There are reasons to like all three of these Robinhood stocks. However, there are also some reasons to stay away from all three.For example, Aphria's disappointing Q4 update earlier this week underscored the challenges the company faces. The COVID-19 pandemic especially impacted its financial performance. But pricing pressures in the Canadian cannabis market are also hurting Aphria.Bionano arguably has the most solid growth prospects of the three companies mentioned. There's one problem that I see, though. Bionano estimates that its total addressable market is between $2.6 billion and $3.8 billion. The company's market cap already stands close to $1.8 billion. Much of Bionano's potential growth is already baked into its share price.What about Ocugen? It's possible that Ocugen could be too late to the party to become a big winner in the U.S. given there are other vaccines already on the market with higher efficacy levels than Covaxin.Maybe Aphria, Bionano Genomics, and/or Ocugen will deliver even greater gains in the remaining months of 2021 than they have in the first part of the year. My view, however, is that there are stocks that offer better risk-reward propositions than these three popular Robinhood stocks.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":45,"commentSize":13,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}